BiPar Sciences Inc. / Sanofi / BiPar Sciences First / /
Country
France / United States / /
Currency
USD / /
Event
FDA Phase / M&A / Company Listing Change / /
IndustryTerm
breast cancer therapies / biopharmaceutical / cancer therapy / treatment of different types of cancers / therapeutic solutions / pharmaceutical / biopharmaceutical company pioneering / therapy for pancreatic cancer / /
MedicalCondition
cancers / ovarian cancer / breast cancers / cancer / tumors / invasive breast cancer / Triple Negative Breast Cancer / prevalent cancer / difficult-to-treat cancer / metastatic triple negative breast cancer / metastases / breakthrough cancer / breast cancer / pancreatic cancer / Commonly used breast cancer / very aggressive cancer / /
MedicalTreatment
breast cancer therapies / chemotherapy / oral therapy / cancer therapy / /
Organization
Federal Trade Commission / /
Person
Hoyoung Huh / Christopher A. Viehbacher / /
Position
Chief Executive Officer / president and Chief Executive Officer / Chief Executive Officer of sanofi-aventis / /
Product
BSI-201 / /
ProvinceOrState
California / /
Technology
gene expression / chemotherapy / treating cancer / SAN / therapeutic solutions / /
Sanofi-aventis To Acquire BiPar Sciences First-in-class oncology medicine will provide new treatment option while adding to the company’s late stage development portfolio BRISBANE, California and PARIS, France – Apri